The influence of n-3 polyunsaturated fatty acids and very low calorie diet during a short-term weight reducing regimen on weight loss and serum fatty acid composition in severely obese women
Language English Country Czech Republic Media print-electronic
Document type Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't
PubMed
15857162
DOI
10.33549/physiolres.930770
PII: 770
Knihovny.cz E-resources
- MeSH
- Phospholipids blood MeSH
- Weight Loss * MeSH
- Caloric Restriction MeSH
- 3-Hydroxybutyric Acid blood MeSH
- Eicosapentaenoic Acid analysis therapeutic use MeSH
- Docosahexaenoic Acids analysis therapeutic use MeSH
- Fatty Acids, Monounsaturated analysis MeSH
- Oleic Acids analysis MeSH
- Middle Aged MeSH
- Humans MeSH
- Obesity blood diet therapy MeSH
- Fatty Acids, Omega-3 analysis therapeutic use MeSH
- Dietary Supplements * MeSH
- Diet, Reducing * MeSH
- Triglycerides blood MeSH
- Check Tag
- Middle Aged MeSH
- Humans MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Clinical Trial MeSH
- Research Support, Non-U.S. Gov't MeSH
- Randomized Controlled Trial MeSH
- Names of Substances
- 11-octadecenoic acid MeSH Browser
- Phospholipids MeSH
- 3-Hydroxybutyric Acid MeSH
- Eicosapentaenoic Acid MeSH
- Docosahexaenoic Acids MeSH
- Fatty Acids, Monounsaturated MeSH
- Oleic Acids MeSH
- Fatty Acids, Omega-3 MeSH
- palmitoleic acid MeSH Browser
- Triglycerides MeSH
Polyunsaturated fatty acids of n-3 series (n-3 PUFA) were shown to increase basal fat oxidation in humans. The aim of the study was to compare the effect of n-3 PUFA added to a very low calorie diet (VLCD), with VLCD only during three-week inpatient weight reduction. Twenty severely obese women were randomly assigned to VLCD with n-3 PUFA or with placebo. Fatty acids in serum lipid fractions were quantified by gas chromatography. Differences between the groups were determined using ANOVA. Higher weight (7.55+/-1.77 vs. 6.07+/-2.16 kg, NS), BMI (2.82+/-0.62 vs. 2.22+/-0.74, p<0.05) and hip circumference losses (4.8+/-1.81 vs. 2.5+/-2.51 cm, p<0.05) were found in the n-3 group as compared to the control group. Significantly higher increase in beta-hydroxybutyrate was found in the n-3 group showing higher ketogenesis and possible higher fatty acid oxidation. The increase in beta-hydroxybutyrate significantly correlated with the increase in serum phospholipid arachidonic acid (20:4n-6; r = 0.91, p<0.001). In the n-3 group significantly higher increase was found in n-3 PUFA (eicosapentaenoic acid, 20:5n-3, docosahexaenoic acid, 22:6n-3) in triglycerides and phospholipids. The significant decrease of palmitoleic acid (16:1n-7) and vaccenic acid (18:1n-7) in triglycerides probably reflected lower lipogenesis. A significant negative correlation between BMI change and phospholipid docosahexaenoic acid change was found (r = -0.595, p<0.008). The results suggest that long chain n-3 PUFA enhance weight loss in obese females treated by VLCD. Docosahexaenoate (22:6n-3) seems to be the active component.
References provided by Crossref.org
